Epithelial Ovarian Cancer
Gabra H. and Blagden S., (2012), Dewhurst's Textbook of Obstetrics & Gynaecology: Eighth Edition, 760 - 775
LARP1 Regulates the Site-specific Synthesis of Proteins Required for Cancer Cell Invasion and Migration
Mura M. et al, (2012), EUROPEAN JOURNAL OF CANCER, 48, S77 - S77
Loss of the Tumor Suppressor Merlin as a Potential Predictive Biomarker of Clinical Activity for the Oral, Focal Adhesion Kinase (FAK) Inhibitor GSK2256098 in Pts with Recurrent Mesothelioma
Soria JC. et al, (2012), EUROPEAN JOURNAL OF CANCER, 48, 188 - 188
MNK 1 and 2 Inhibitors Are Active in Platinum-resistant Ovarian Cancer Cells
Mura M. et al, (2012), EUROPEAN JOURNAL OF CANCER, 48, 26 - 26
Molecular and cellular effects of oncogene cooperation in a genetically accurate AML mouse model
Reckzeh K. et al, (2012), Leukemia, 26, 1527 - 1536
Multivariate screening of prognostic factors to identify a novel, simple, and objective marker to optimize patient selection and predict survival benefit in early-phase trials.
Stavraka C. et al, (2012), JOURNAL OF CLINICAL ONCOLOGY, 30
Pharmacokinetics/pharmacodynamics (PK/PD) of GSK2256098, a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with Advanced Solid Tumors
Gan H. et al, (2012), EUROPEAN JOURNAL OF CANCER, 48, 189 - 189
Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer.
Coley HM. et al, (2012), Oncotarget, 3, 78 - 83
Use of inflammation-based scores to optimize the selection of patients with advanced cancer considered for early-phase clinical trials
Pinato DJ. et al, (2012), JOURNAL OF CLINICAL ONCOLOGY, 30
A phase 3 trial of bevacizumab in ovarian cancer.
Perren TJ. et al, (2011), N Engl J Med, 365, 2484 - 2496
A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.
Leijen S. et al, (2011), Cancer Chemother Pharmacol, 68, 1619 - 1628
Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mononuclear cells.
Sabharwal A. et al, (2011), Melanoma Res, 21, 502 - 508
FLT3-ITDs Introduce a Myeloid Differentiation and Transformation Bias to Multipotent Lympho-Myeloid Progenitors
Mead AJ. et al, (2011), BLOOD, 118, 604 - 604
Germline Activating JAK2 V617I Mutation, in a Family with Hereditary Thrombocytosis
Mead AJ. et al, (2011), BLOOD, 118, 758 - 759
The Effect of Eltrombopag on Platelet Resistance to Apoptosis: The Role of the Bcl-Xl Pathway
Mitchell WB. et al, (2011), BLOOD, 118, 524 - 524
Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia.
Psaila B. et al, (2011), J Thromb Haemost, 9, 2302 - 2310
Periampullary Cancer ESPAC-3(v2) trial: a Randomised Controlled Phase III Trial of Adjuvant Chemotherapy Versus Observation in Patients With Periampullary Adenocarcinomas of the Head of the Pancreas
Neoptolemos J. et al, (2011), PANCREAS, 40, 1343 - 1343
Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer (vol 104, pg 1822, 2011)
Khan OA. et al, (2011), BRITISH JOURNAL OF CANCER, 105, 1252 - 1252
Erratum: Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer (British Journal of Cancer (2011) 104 (1822-1827) DOI:10.1038/bjc.2011.154)
Khan OA. et al, (2011), British Journal of Cancer, 105